ClinicalTrials.gg
Enrolling by invitationNCT06253507Updated Nov 18, 2026

pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)

A Phase 1/2 interventional study of Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47 in p47, Autosomal Recessive and Chronic Granulomatous Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Enrolling by invitation at 1 site in United States. Open to participants aged 3 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
3 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) — 7 open to participants now, 10 under way, none of them phase 3. Granulomatous Disease, Chronic · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
12th of 24
10 · median 10
Started
2024
with 2 others
Phase 1/2
8 of 31
4 open now
Registered
29th of 31
by date

Among the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 12th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 8 in phase 1/2, and was the 29th registered.

Granulomatous Disease, Chronic

79 studies on the registry are indexed under Granulomatous Disease, Chronic; 17 are open to participants now.

Browse Granulomatous Disease, Chronic studies →

Open to participants now

7 of the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 12 Granulomatous Disease, Chronic studies recruiting now, 3 (25%) set no upper age limit and 9 (75%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 3 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Chronic granulomatous disease (CGD) is a genetic disorder. People with CGD are missing a gene that affects their white blood cells. White cells are part of the immune system, and people with GCD are vulnerable to many infections. Researchers want to test a new treatment to replace the missing gene that may be safer than the current treatment for CGD.

Objective:

To test a new type of gene therapy in people with CGD.

Eligibility:

People aged 3 years or older with CGD.

Design:

Participants will undergo apheresis: Blood will be collected through a tube attached to a needle inserted in a vein; the blood will run through a machine that separates certain cells (stem cells); the remaining blood will be returned to the body through a second needle. The participant s stem cells will be modified in a laboratory to add the gene they are missing.

Participants will stay in the hospital for about 40 days.

For the first 10 days, they will undergo many exams, including imaging scans and tests of their heart and lung function. They will receive drugs to prepare their bodies for the gene therapy. They will receive a "central line": A hollow tube will be inserted into a vein in the chest, with a port opening above the skin. This port will be used to draw blood and administer drugs without the need for new needle sticks.

For the gene therapy, each participant s own modified stem cells will be put into their body through the port.

Participants will have 8 follow-up visits over 3 years.

Read the detailed description

Study Description:

This is a phase I/II, non-randomized, open-label study of a single infusion of autologous CD34+ cells transduced ex vivo with pCCLCHIM-p47 in 5 patients with p47-AR CGD conditioned with high dose busulfan.

Objectives:

Primary Objectives:

To evaluate the efficacy of pCCLCHIM-p47 transduced autologous CD34+ cells treatment in p47 AR-CGD patients as measured by engraftment of genetically modified cells at 6 months.

Secondary Objectives:

  • Safety
  • Long term engraftment (assessments at 1 year, 2 years, and 3 years)
  • Event Free Survival
  • Clinical Efficacy and Health Assessment

Exploratory Objectives:

  • Assessment of biomarker utility
  • Evaluation of the human microbiome during pCCLCHIM-p47 gene therapy.
  • Patient reported assessment of efficacy (QOL)

Endpoints:

Primary Endpoint of this study will be engraftment of genetically modified cells as defined by presence of >10% oxidase positive cells at 6 months.

  • Secondary Endpoints will consist of:
  • Safety: assessed by recording of the incidence of adverse events.

    • Record clinical adverse events and clinically significant laboratory abnormalities.
    • Evaluate overall incidence of adverse events for the study as a whole.
    • Monitor the incidence of serious adverse events.
    • Measure overall survival at 3 years post-transplant
    • Assessment of vector safety by vector insertion site analysis (VISA) and replication competent lentivector (RCL) testing.
  • Long term multilineage engraftment, as measured by:

    • Expression of p47 phox in neutrophils at 6, 12, 18, 24, and 36 months.
    • Hematological reconstitution by 90 days post treatment (absolute neutrophil count >500 cells/microliter on three consecutive samples over at least ten days).
    • NADPH Oxidase activity in monocytes by dihydrorhodamine (DHR) flow cytometry at 6, 12, 18, 24, and 36 months.
    • Percentage of gene modified CD34+ hemopoietic cells in BM at 6, 12, 18, 24, 30, and 36 months as assessed by vector copy number (VCN) qPCR.
    • VCN in cell lineages present in PB cells at months 1, 3, 6, 9, 12, 18, 24, and 36.
  • Event free Survival

    • Resolution of either underlying inflammation and/or infection related to P47 deficiency without recurrence for 3 years.
    • Rate of severe (as defined by CTCAE v 5.0 - grade 3 to 5) CGD related infections after withdrawal of antimicrobial prophylaxis in time periods 6-12 and 6-36 months post treatment.
  • Assessment of clinical efficacy and health by:

    • The nutritional status (height, weight, serum albumin) at 36 months.
    • Growth and development of pediatric subjects at 36 months.
    • Frequency of severe infections (days requiring IV antibiotics and/or hospitalization for treatment) at 36 months.
    • Presence of inflammatory complications (days requiring hospitalizations) at 36 months.

Tertiary Endpoints:

  • Utility of Biomarker assessment
  • Stool collection for microbiome analysis (optional)
  • Patient Quality of life questionnaire collection
03

Conditions studied

  • p47
  • Autosomal Recessive
  • Chronic Granulomatous Disease

Keywords

  • p47 Phox
  • Autosomal Recessive
  • Chronic Granulomatous Disease
  • Gene Therapy
  • Lenti Vector
04

Who can participate

Ages eligible
3 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

-Must have confirmed genetic diagnosis of p47 AR-CGD by identification of a mutation in the responsible genes or protein analysis demonstrating lack of P47 expression and supported by laboratory evidence for absent or reduction > 95% of the biochemical

activity of the NADPH-oxidase.

  • Must weigh at least 15 kg.
  • Adult Patient must be willing to sign and date form.
  • Parent/guardian must be willing to sign and date informed consent form for child and where appropriate, child may sign assent.
  • State willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female must be at least 3 years of age.
  • Do not have an appropriately HLA matched donor (related or unrelated)
  • Must have had at least a history of a prior CGD related infection and/or an ongoing/ severe infection requiring hospitalization and/or inflammatory complications requiring hospitalization despite conventional therapy.
  • Patients will be collected as per standard of care mobilization and apheresis procedures as performed at the Clinical Center or at their local facility. Patients will have consented onto the gene therapy study prior to collection; however products collected prior to the study for other protocols may be used as part of the back up.

    • Patient must weigh at least 15 kilograms body weight
    • Normal female donors of may be entered if using effective and having a negative serum pregnancy test within one week of beginning G-CSF administration.
  • Ability to take oral medication and be willing to adhere to the prophylactic regimen.
  • For females of , must agree to use 2 forms of highly effective contraception throughout study participation (for a minimum of 3 months after having received the genetically modified cells but preferably for the first 2 years.)

    • For females (will be counseled on appropriate combinations for best efficacy):

      • Condoms, male or female, with or without a spermicide.
      • Diaphragm or cervical cap with spermicide.
      • Intrauterine device.
      • Contraceptive pills or patch, Norplant, Depo-Provera, or other FDAapproved contraceptive method.
      • Having a male partner who has previously undergone a vasectomy.
    • For males of reproductive potential: use of condoms or other methods to ensure effective contraception prevention with partner.
  • Agreement to adhere to Lifestyle Considerations throughout study duration.
  • Must provide a durable power of attorney (DPA) for health care decisions to an appropriate adult relative or guardian in accordance to NIH-200 "NIH Advance Directive for Health Care and Medical Research Participation".
  • All patients must be willing to allow storage of blood samples for gene therapy studies.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Patient/Parent/Guardian unable or unwilling to comply with the protocol requirements.
  • for leukapheresis (anemia \<8g/dL, cardiovascular instability, severe coagulopathy, uncontrolled seizure disorder).
  • Pregnancy or lactation.
  • Tested positive (definitive) for the presence of multiple types (2 or more) of anti- antibodies.
  • Patient will be excluded if they have any of the following within 8 weeks of entering the trial.

    • Hematologic

      • Anemia (hemoglobin \< 8 g/dL).
      • Neutropenia (absolute granulocyte count \<1,000/mm3)
      • Thrombocytopenia (platelet count \< 100,000/mm3).
      • (PT) or Partial thromboplastin time (PTT) > 2 X the (ULN) (Patients with a correctable deficiency controlled on medication will not be excluded).
      • Cytogenetic abnormalities known to be associated with hematopoietic defect on peripheral blood or bone marrow.
    • Infectious

      ---Evidence of infection with -1 and -2, or active , , Adenovirus, Parvovirus, Toxoplasmosis, or any other uncontrolled viral infection.

    • Pulmonary

      ---Resting O2 saturation by pulse oximetry \< 90% on room air.

    • Cardiac

      • by Echocardiogram of less than 40%;

OR

---Uncorrected congenital cardiac malformation with clinical symptomatology;

OR

  • Abnormal which with additional work up (including a Cardiology consult) indicates cardiac pathology incompatible with the use of high dose busulfan.

    --Hepatic

  • Transaminases >5X upper limit of normal.

    • General

      • Expected survival \< 6 months.
      • Major congenital anomaly.
      • Contraindication for administration of conditioning medication.
      • Current or active or prior hematologic malignancy.
      • Uncontrolled hypertension (systolic greater than 1 SD of the mean expected for age despite adequate medication).
      • Uncontrolled tachycardia with resting heart rate greater than 1 standard deviation for age group despite medications.
      • Neurologic deficits determined to interfere with ability to comply with study interventions.
    • Known serious or anaphylactic allergic reactions to components of the Busulfan or to DMSO.
    • Treatment with another drug or other intervention within 6 months.
    • Unable to undergo apheresis:

      • Patients who are hemodynamically unstable (systolic or diastolic blood pressure fall of 20 mm Hg from the stable patient s baseline measurement) or requiring mechanical respiratory assistance are excluded.
      • History of vasculitis or any illness that precludes apheresis as defined by the Cellular Engineering Department.
    • Administration of gamma-interferon within 21 days before the infusion of transduced, autologous CD34+ cells
    • Acute infection diagnosed but not treated at time of enrollment. Patients will be delayed for enrollment until infection has resolved or if not resolving with adequate standard medical care, the patient will then be re-eligible for treatment as this would have them meeting the inclusion criteria of a infection. (Patients that develop an infection during the conditioning [after enrollment and having started the busulfan] will proceed with the study.)
    • Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful study completion.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Single arm

    Biological: Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47

Interventions

  • BiologicalCryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47

    Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use. The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg.

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of pCCLCHIM-p47 transduced autologous CD34+ cells treatment in p47 AR-CGD patients as measured by engraftment of genetically modified cells.

    Time frame: 6 months to 1 year.

Secondary outcomes

  1. Safety

    assessed by recording of the incidence of adverse events for the study as a whole

    Time frame: Length of study

  2. Long term Engraftment

    Time frame: 6, 12, 18, 24, and 36 months

  3. Event Free Survival

    Time frame: 3 years

  4. Clinical Efficacy and Health Assessment

    Time frame: 24 and 36 months

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 12, 2024
StartActual
Jun 25, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06253507
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Jun 25, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Elizabeth M Kang, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion